Deferred Tax Assets, Valuation Allowance in USD of Chemomab Therapeutics Ltd. from Q4 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Chemomab Therapeutics Ltd. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2018 to Q4 2024.
  • Chemomab Therapeutics Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $44,219,000, a 1.7% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Chemomab Therapeutics Ltd. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $44,219,000 +$748,000 +1.7% 31 Dec 2024 20-F 04 Apr 2025 2024 FY
Q4 2023 $43,471,000 +$2,276,000 +5.5% 31 Dec 2023 20-F 04 Apr 2025 2024 FY
Q4 2022 $41,195,000 +$5,165,000 +14% 31 Dec 2022 20-F 04 Apr 2025 2024 FY
Q4 2021 $36,030,000 +$29,830,000 +481% 31 Dec 2021 20-F 04 Apr 2025 2024 FY
Q4 2020 $6,200,000 +$1,952,000 +46% 31 Dec 2020 20-F 28 Mar 2024 2023 FY
Q4 2019 $4,248,000 -$15,321,000 -78% 31 Dec 2019 10-K 30 Mar 2022 2021 FY
Q4 2018 $19,569,000 31 Dec 2018 10-K 17 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.